{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:55:07Z","timestamp":1785840907836,"version":"3.56.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bmc.2022.117073","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T21:48:26Z","timestamp":1667339306000},"page":"117073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone"],"prefix":"10.1016","volume":"75","author":[{"given":"Wanqiu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.117073_b0005","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s12325-016-0346-1","article-title":"Comorbidity burden in trial-aligned patients with established gout in Germany, UK, US, and France: a retrospective analysis","volume":"33","author":"Nyberg","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.bmc.2022.117073_b0010","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/annrheumdis-2013-204680","article-title":"The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study","volume":"73","author":"Smith","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmc.2022.117073_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101719","article-title":"Treatment advances in gout","volume":"35","author":"Stamp","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.bmc.2022.117073_b0020","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.semarthrit.2020.04.010","article-title":"Therapeutic approaches in the treatment of gout","volume":"50","author":"Pillinger","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.bmc.2022.117073_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102241","article-title":"Emerging strategies for treating gout","volume":"65","author":"Huddleston","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bmc.2022.117073_b0030","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1021\/acs.jmedchem.1c02057","article-title":"Discovery of novel bicyclic imidazolopyridine-containing human urate transporter 1 inhibitors as hypouricemic drug candidates with improved efficacy and favorable druggability","volume":"65","author":"Zhao","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.117073_b0035","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1016\/j.bmc.2011.07.039","article-title":"N-(1,3-Diaryl-3-oxopropyl)amides as a new template for xanthine oxidase inhibitors","volume":"19","author":"Nepali","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2022.117073_b0040","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/j.ejmech.2010.02.013","article-title":"Synthesis of some 5-phenylisoxazole-3-carboxylic acid derivatives as potent xanthine oxidase inhibitors","volume":"45","author":"Wang","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.117073_b0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.2012.04207.x","article-title":"The pharmacokinetics of oxypurinol in people with gout","volume":"74","author":"Stocker","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2022.117073_b0050","first-page":"61","article-title":"Benzbromarone in the treatment of gout","volume":"18","author":"Kawenoki-Minc","year":"1980","journal-title":"Reumatologia"},{"key":"10.1016\/j.bmc.2022.117073_b0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00003495-197714050-00002","article-title":"Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia","volume":"14","author":"Heel","year":"1977","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2022.117073_b0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40266-017-0461-y","article-title":"Lesinurad: A Review in Hyperuricaemia of Gout","volume":"34","author":"Deeks","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bmc.2022.117073_b0065","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjmed.2006.06.040","article-title":"Ford ESJAJoM: prevalence of the metabolic syndrome in individuals with hyperuricemia","volume":"120","author":"Choi","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.bmc.2022.117073_b0070","doi-asserted-by":"crossref","unstructured":"Ju-Mi, Lee, Hyeon, et al. Association between serum uric acid level and metabolic syndrome 2012;45:181\u20137. https:\/\/doi.org\/10.3961\/jpmph.2012.45.3.181.","DOI":"10.3961\/jpmph.2012.45.3.181"},{"key":"10.1016\/j.bmc.2022.117073_b0075","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"Richette","year":"2009","journal-title":"Gout. Lancet"},{"key":"10.1016\/j.bmc.2022.117073_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174291","article-title":"A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: current therapeutic options and potential applications","volume":"907","author":"Song","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2022.117073_b0085","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/molecules23020252","article-title":"Systematic structure-activity relationship (SAR) exploration of diarylmethane backbone and discovery of a highly potent novel uric acid transporter 1 (URAT1) inhibitor","volume":"23","author":"Cai","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2022.117073_b0090","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5738900","article-title":"Recent updates of natural and synthetic URAT1 inhibitors and novel screening methods","volume":"2021","author":"Chen","year":"2021","journal-title":"Evid-Based Complement Alternat Med: eCAM"},{"key":"10.1016\/j.bmc.2022.117073_b0095","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3390\/molecules26041071","article-title":"Loganin alleviates gout inflammation by suppressing NLRP3 inflammasome activation and mitochondrial damage","volume":"26","author":"Choi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2022.117073_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104262","article-title":"Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver","volume":"104","author":"Qiu","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2022.117073_b0105","first-page":"9","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2022.117073_b0110","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1038\/ncomms7115","article-title":"Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome","volume":"6","author":"Yang","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2022.117073_b0115","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","article-title":"Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis","volume":"25","author":"Hao","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.bmc.2022.117073_b0120","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1039\/D0RA09320C","article-title":"Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists","volume":"11","author":"Zhao","year":"2021","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2022.117073_b0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2009","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2022.117073_b0130","unstructured":"Delano WLJPSF. Bioinformatics: the PyMol molecular graphics system. Proteins Struct Functi Bioinform 2002;30:442\u201354."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622004667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622004667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:19:50Z","timestamp":1760836790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622004667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"alternative-id":["S0968089622004667"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117073","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117073"}}